Integral Health Asset Management LLC Has $2.49 Million Holdings in Terns Pharmaceuticals, Inc. (NASDAQ:TERN)

Integral Health Asset Management LLC boosted its position in Terns Pharmaceuticals, Inc. (NASDAQ:TERN) by 50.0% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 450,000 shares of the company’s stock after buying an additional 150,000 shares during the quarter. Integral Health Asset Management LLC’s holdings in Terns Pharmaceuticals were worth $2,493,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also bought and sold shares of TERN. Landscape Capital Management L.L.C. acquired a new stake in Terns Pharmaceuticals in the 4th quarter worth $73,000. Townsquare Capital LLC acquired a new stake in shares of Terns Pharmaceuticals during the 4th quarter valued at about $76,000. Oxford Asset Management LLP acquired a new stake in shares of Terns Pharmaceuticals during the 4th quarter valued at about $86,000. Savant Capital LLC acquired a new stake in shares of Terns Pharmaceuticals during the 4th quarter valued at about $89,000. Finally, China Universal Asset Management Co. Ltd. boosted its position in shares of Terns Pharmaceuticals by 33.1% during the 4th quarter. China Universal Asset Management Co. Ltd. now owns 18,010 shares of the company’s stock valued at $100,000 after acquiring an additional 4,475 shares in the last quarter. 98.26% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Several analysts have recently weighed in on TERN shares. JMP Securities reiterated a “market outperform” rating and set a $20.00 target price on shares of Terns Pharmaceuticals in a research report on Monday, April 21st. William Blair reiterated a “market perform” rating on shares of Terns Pharmaceuticals in a research report on Friday, March 21st. Two equities research analysts have rated the stock with a hold rating and three have assigned a buy rating to the stock. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus price target of $18.38.

Terns Pharmaceuticals Price Performance

Shares of NASDAQ:TERN opened at $3.04 on Monday. Terns Pharmaceuticals, Inc. has a one year low of $1.87 and a one year high of $11.40. The company has a 50 day moving average of $2.90 and a 200-day moving average of $4.58. The stock has a market cap of $265.50 million, a price-to-earnings ratio of -2.58 and a beta of -0.16.

Terns Pharmaceuticals (NASDAQ:TERN) last issued its earnings results on Monday, May 12th. The company reported ($0.26) EPS for the quarter, beating the consensus estimate of ($0.29) by $0.03. Equities research analysts anticipate that Terns Pharmaceuticals, Inc. will post -1.19 earnings per share for the current year.

Terns Pharmaceuticals Company Profile

Terns Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops small-molecule product candidates for the treatment of oncology, metabolic dysfunction-associated steatohepatitis (MASH), and obesity. The company develops TERN-701, an allosteric BCR-ABL tyrosine kinase inhibitor (TKI) that is in phase 1 clinical trial for chronic myeloid leukemia (CML), a form of cancer that starts in bone marrow.